<p>Development of mitral and tricuspid devices has exploded, although the number of procedures is still limited. Women are under-represented in clinical trials, and in many trials, outcomes are not specified for sex. In mitral and tricuspid trials, the sex distribution is more even than in transcatheter aortic valve implantation (TAVI) trials. In these trials, in general, females are older, have more bleeding complications, and have less kidney injury than men. Procedural results are good. Long-term observation is still not available because of short observation time. In tricuspid procedures, other factors than device success play a role, like right heart failure, pulmonary hypertension, and atrial fibrillation. We should, for the future, focus more on differences in outcome between men and women to better customize treatment options.</p> Graphical Abstract <p>Transcatheter mitral and tricuspid interventions, outcomes in women. Generated by AI.</p> <p></p>